Abstract
Intensive care unit (ICU) sedation with sevoflurane is associated with nephrogenic diabetes insipidus. Given that isoflurane is now licenced (in Europe) for ICU sedation and has Investigational New Drug status in the USA, evidence indicates that clinicians should stop using sevoflurane in this indication except in the context of clinical trials.
Original language | English |
---|---|
Pages (from-to) | 7-10 |
Number of pages | 4 |
Journal | British Journal of Anaesthesia |
Volume | 129 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jul 2022 |
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Keywords
- acute kidney injury
- diabetes insipidus
- isoflurane
- nephrotoxicity
- sedation
- sevoflurane